Background Convalescent plasma therapy is a leading treatment for conferring temporary
immunity to COVID-19–susceptible individuals or for use as post-exposure prophylaxis …

BACKGROUND Neutralizing antibodies are considered a key correlate of protection by
current SARS-CoV-2 vaccines. The manner in which human infections respond to …

Background Convalescent plasma therapy for COVID‐19 relies on transfer of anti‐viral
antibody from donors to recipients via plasma transfusion. The relationship between clinical …

BACKGROUND SARS-CoV-2–specific antibodies may protect from reinfection and disease,
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …

Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …

Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …

We evaluated the antibody responses in 259 potential convalescent plasma donors for
Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies …

Newly emerged pathogens such as SARS-CoV-2 highlight the urgent need for assays that
detect levels of neutralizing antibodies that may be protective. We studied the relationship …

Background Antibody response duration following severe acute respiratory syndrome
coronavirus 2 infection tends to be variable and depends on severity of disease and method …

In the absence of effective vaccines and with limited therapeutic options, convalescent
plasma is being collected across the globe for potential transfusion to coronavirus disease …